Protgen Ltd
13
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials
Role: lead
Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects
Role: lead
Recombinant Human Serum Albumin in Healthy Subjects
Role: lead
Phase II/III of Recombinant Human Serum Albumin
Role: lead
Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites
Role: lead
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Role: lead
Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer
Role: lead
Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer
Role: lead
Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer
Role: lead
Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
Role: lead
Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors
Role: lead
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Role: lead
Single-dose Escalation Trial of M2ES in Healthy Volunteer
Role: lead
All 13 trials loaded